trending Market Intelligence /marketintelligence/en/news-insights/trending/tnyy7mnrphrosor5iagsbg2 content esgSubNav
In This List

Report: MiMedx facing US DOJ probe over business practices

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


Report: MiMedx facing US DOJ probe over business practices

The U.S. Justice Department is investigating whether biotech firm MiMedx Group Inc. overcharged the government for its tissue repair products, Bloomberg News reported, citing anonymous sources.

The regulator is also looking into the Georgia-based company's distribution practices, including whether it improperly recorded sales of products that were not ordered, a practice known as channel stuffing.

MiMedx said it is not aware of any such investigations, the news outlet reported citing a company statement.

MiMedx's stock price was down 10.73% to $6.99 as of 12:44 p.m. ET on Feb. 26.